The COVID-19 pandemic has highlighted the important role that polymerase chain reaction (PCR) can play in molecular diagnostics. PCR-based testing quickly became the predominant method used to identify infected individuals and stem chains of transmission. However, traditional PCR technologies depend on RNA or DNA extraction before PCR testing, which adds time and costs to the workflow.
Technology Networks spoke to Dr. George Huang, chief financial officer at Entopsis, to learn how these steps can be omitted using direct PCR technology. In this interview, Dr. Huang also discusses the advantages of this approach, why uptake has so far not been greater and what sets next generation direct PCR reagents apart.